In fact, in the circular of 11 June, Rezza himself specified that “for people who have received the first dose of this vaccine and are under 60 years of age, the cycle must be completed with a second dose of mRNA vaccine (Comirnaty or Moderna), to be administered 8-12 weeks after the first dose ».
The opinion of the CTS of 11 June
In the opinion of the CTS of 11 June, it must be said, a peremptory indication was not expressed, as the Ministry of Health then chose to do, in favor of the use of mRna vaccines after the first dose of Astrazeneca in subjects under 60 years of age. In that document, in fact, the experts of the Committee, after a long introduction on the epidemiological scenario and the positive developments recorded following vaccinations in terms of controlling the spread of the epidemic, first of all wrote “that, as regards the second dose, it is recommended continue administration with the Vaxzevria vaccine for subjects over sixty years of age ‘.
The orientation expressed by the technicians
Below sixty, we read in the opinion of 11 June, “although, as mentioned above, thrombotic phenomena are much less frequently associated with the administration of the second dose, in compliance with a principle of maximum caution inspired to prevent the onset of Vitt phenomena in subjects at extremely low risk of developing serious Covid-19 pathology, as well as in compliance with the above-mentioned principle of fair treatment, it is considered advisable the use of an mRNA vaccine in subjects under the age of 60. The administration of the second mRNA dose should take place – on the basis of available studies – at a distance of between 8 and 12 weeks from the administration of the first dose of Vaxzevria ».